Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
mRNA-1647 in liver transplant candidates
NCT06133010Phase 2Withdrawn
- Sponsor
- Moderna Inc
- Start
- Feb 2024
- Primary completion
- Feb 2027
- Modality
- Vaccines & Immunotherapeutics, Lipid-based Nanoparticles, mRNA Therapeutics
01
Overview
A Phase 2 trial of mRNA-1647 in cytomegalovirus infection (CMV), sponsored by Moderna Inc. Planned start Feb 2024; status: withdrawn.
02
Drugs
mRNA-1647
03
Conditions
cytomegalovirus infection (CMV)
Beyond the preview
Go deeper on NCT06133010.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06133010.